The aim of the FLIP consortium (Fatty Liver Inhibition of Progression) is to understand and prevent the progression of NAFLD to its more severe forms.
The main outcomes of FLIP will be:
New insights into its progression, particularly in terms of identifying the initiating mechanisms and patients at risk.
Developing innovative diagnostic methods adapted for largescale screening and prognostic evaluation.
Characterising the key pathways and molecular targets amenable to pharmacological therapy, and finally, the improvement of implementation of lifestyle changes.